US Vaccine Study in Guinea-Bissau Suspended Amid Controversy Over Ethics and Sovereignty
Guinea-Bissau has cancelled a US-funded vaccine study on hepatitis B vaccination after major changes to the US vaccination schedule raised questions about the ethics of conducting such research in other countries. The move comes as international health officials, including those from the Africa Centres for Disease Control and Prevention (Africa CDC), defend the study's integrity.
According to Quinhin Nantote, Guinea-Bissau's new minister of health, the trial was suspended due to concerns over the science behind it. A team of researchers will travel to Guinea-Bissau to help review the study and ensure its conduct meets international standards.
However, US officials have called into question the credibility of Africa CDC, claiming that the organization is waging a "public-relations campaign" aimed at shaping public perception rather than engaging with scientific facts. They also described the Africa CDC as a "powerless, fake organization attempting to manufacture credibility".
In contrast, Abdulhammad Babatunde, a medical doctor and global health researcher in Nigeria, argues that Africans want to solve their own problems, not just satisfy the curiosity of funders. He notes that the study's design is unacceptable, particularly since infants would be given vaccines at birth or withheld until six weeks old.
The World Health Organization recommends administering the hepatitis B vaccine within 24 hours of birth. Guinea-Bissau currently has limited access to healthcare and vaccination services, with nearly one in five adults and about 11% of young children having hepatitis B.
Guinea-Bissau's government has taken a firm stance on its sovereignty, insisting that international organizations or foreign countries should not dictate research decisions. Director-general of Africa CDC, Jean Kaseya, said, "It's the sovereignty of the country. I don't know what will be this decision, but I will support the decision that the minister will make."
As controversy surrounding the study unfolds, concerns are being raised about the need for greater transparency and accountability in research conducted in low-resource countries. The international community is urged to respect Guinea-Bissau's sovereignty while promoting evidence-based research practices.
The country faces significant healthcare challenges, including limited access to basic services such as water and sanitation, poverty, food insecurity, high maternal mortality rates, and malaria being a leading cause of death. Despite these hurdles, Guinea-Bissau's authorities are committed to addressing these issues.
As the situation continues to evolve, it is essential for all parties involved to prioritize transparency, ethics, and respect for sovereignty in research practices.
Guinea-Bissau has cancelled a US-funded vaccine study on hepatitis B vaccination after major changes to the US vaccination schedule raised questions about the ethics of conducting such research in other countries. The move comes as international health officials, including those from the Africa Centres for Disease Control and Prevention (Africa CDC), defend the study's integrity.
According to Quinhin Nantote, Guinea-Bissau's new minister of health, the trial was suspended due to concerns over the science behind it. A team of researchers will travel to Guinea-Bissau to help review the study and ensure its conduct meets international standards.
However, US officials have called into question the credibility of Africa CDC, claiming that the organization is waging a "public-relations campaign" aimed at shaping public perception rather than engaging with scientific facts. They also described the Africa CDC as a "powerless, fake organization attempting to manufacture credibility".
In contrast, Abdulhammad Babatunde, a medical doctor and global health researcher in Nigeria, argues that Africans want to solve their own problems, not just satisfy the curiosity of funders. He notes that the study's design is unacceptable, particularly since infants would be given vaccines at birth or withheld until six weeks old.
The World Health Organization recommends administering the hepatitis B vaccine within 24 hours of birth. Guinea-Bissau currently has limited access to healthcare and vaccination services, with nearly one in five adults and about 11% of young children having hepatitis B.
Guinea-Bissau's government has taken a firm stance on its sovereignty, insisting that international organizations or foreign countries should not dictate research decisions. Director-general of Africa CDC, Jean Kaseya, said, "It's the sovereignty of the country. I don't know what will be this decision, but I will support the decision that the minister will make."
As controversy surrounding the study unfolds, concerns are being raised about the need for greater transparency and accountability in research conducted in low-resource countries. The international community is urged to respect Guinea-Bissau's sovereignty while promoting evidence-based research practices.
The country faces significant healthcare challenges, including limited access to basic services such as water and sanitation, poverty, food insecurity, high maternal mortality rates, and malaria being a leading cause of death. Despite these hurdles, Guinea-Bissau's authorities are committed to addressing these issues.
As the situation continues to evolve, it is essential for all parties involved to prioritize transparency, ethics, and respect for sovereignty in research practices.